Iferanserin

Summary

Iferanserin (CHEMBL3989686) is a phase-3 clinical-stage small molecule; indicated across 1 condition including hemorrhoid.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 2
• Chemistry: 348.5 Da · C23H28N2O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3989686
Name	Iferanserin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	6445539
Molecular formula	C23H28N2O
Molecular weight	348.5
InChIKey	UXIPFQUBOVWAQW-UEBLJOKOSA-N

SMILES: CN1CCCC[C@H]1CCC2=CC=CC=C2NC(=O)/C=C/C3=CC=CC=C3

IUPAC name: (E)-N-[2-[2-[(2S)-1-methylpiperidin-2-yl]ethyl]phenyl]-3-phenylprop-2-enamide

Also known as: Iferanserin, Iferanserina, Iferanserine, S-mpec, Ven-309, IFERANSERIN

Patent coverage: 47 distinct patent families (112 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
hemorrhoid	3	MONDO:0004872	EFO:0009552

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01355874	PHASE3	TERMINATED	Efficacy and Safety Study to Treat Subjects With Symptomatic Internal Hemorrhoids
NCT01483833	PHASE2	COMPLETED	Efficacy Study of Iferanserin to Treat Hemorrhoids

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).